Open Nav

Using Microbiome-Based Therapies to Improve Patient Outcomes

  • Wenyuan Shi, Forsyth Institute,
  • David Berry , Flagship Pioneering,
  • Karim Dabbagh, Second Genome, Inc.,
  • Glyn Edwards, Summit Therapeutics,
  • Paul Miller, Synlogic,
  • Lihi Segal, DayTwo,
  • Emma Taylor, Naked Biome

Investments in microbiome-related companies have accelerated across the past three years, demonstrating high investor expectations for results. As the first pioneering companies have pushed research into clinical development and started publishing results, those findings and new avenues beyond the gut and digestion-related therapies suggest diagnostic and treatment opportunities in inflammation, neurology, and dermatology, among others. This panel will discuss a range of microbiome-based approaches for innovations to improve patient outcomes. Topics include microbiome transplants, bioengineered probiotics, next-generation antibiotics, and microbiome-based drug discovery platforms.

Moderator: Wenyuan Shi, PhD, Chief Executive Officer and Chief Scientific Officer, Forsyth Institute

  • Date:Wednesday, October 17
  • Time:10:45 AM - 11:40 AM
  • Session Type:Educational Session
Wenyuan Shi
Forsyth Institute
David Berry
Flagship Pioneering
Karim Dabbagh
Second Genome, Inc.
Glyn Edwards
Summit Therapeutics
Paul Miller
Lihi Segal
Emma Taylor
Naked Biome